GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Biologic Products Holdings Inc (NAS:CBPO) » Definitions » Current Ratio

China Biologic Products Holdings (China Biologic Products Holdings) Current Ratio : 12.01 (As of Sep. 2020)


View and export this data going back to 2001. Start your Free Trial

What is China Biologic Products Holdings Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. China Biologic Products Holdings's current ratio for the quarter that ended in Sep. 2020 was 12.01.

China Biologic Products Holdings has a current ratio of 12.01. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for China Biologic Products Holdings's Current Ratio or its related term are showing as below:

CBPO' s Current Ratio Range Over the Past 10 Years
Min: 1.03   Med: 4.66   Max: 12.62
Current: 12.01

During the past 13 years, China Biologic Products Holdings's highest Current Ratio was 12.62. The lowest was 1.03. And the median was 4.66.

CBPO's Current Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.8 vs CBPO: 12.01

China Biologic Products Holdings Current Ratio Historical Data

The historical data trend for China Biologic Products Holdings's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biologic Products Holdings Current Ratio Chart

China Biologic Products Holdings Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.15 5.30 6.07 11.09 10.89

China Biologic Products Holdings Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.47 10.89 10.51 11.32 12.01

Competitive Comparison of China Biologic Products Holdings's Current Ratio

For the Biotechnology subindustry, China Biologic Products Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Biologic Products Holdings's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Biologic Products Holdings's Current Ratio distribution charts can be found below:

* The bar in red indicates where China Biologic Products Holdings's Current Ratio falls into.



China Biologic Products Holdings Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

China Biologic Products Holdings's Current Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Current Ratio (A: Dec. 2019 )=Total Current Assets (A: Dec. 2019 )/Total Current Liabilities (A: Dec. 2019 )
=1299.725/119.309
=10.89

China Biologic Products Holdings's Current Ratio for the quarter that ended in Sep. 2020 is calculated as

Current Ratio (Q: Sep. 2020 )=Total Current Assets (Q: Sep. 2020 )/Total Current Liabilities (Q: Sep. 2020 )
=1494.958/124.449
=12.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Biologic Products Holdings  (NAS:CBPO) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


China Biologic Products Holdings Current Ratio Related Terms

Thank you for viewing the detailed overview of China Biologic Products Holdings's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


China Biologic Products Holdings (China Biologic Products Holdings) Business Description

Traded in Other Exchanges
N/A
Address
19 Chaoyang Park Road, 18th Floor, Jialong International Building, Chaoyang District, Beijing, CHN, 100125
China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.
Executives
Zhijing Cbpo Liu officer: Corporate Vice President 19 CHAOYANG PARK ROAD 18/F, JIALONG INTERNATIONAL BUILDING BEIJING F4 100125
Sean Shao director 21ST FLOOR, EVERBRIGHT BANK BUILDING, ZHUZILIN, FUTIAN DISTRICT, SHENZHEN, GUANGDONG F4 518040
David Gao director, officer: Chief Executive Officer C/ BEIJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Albert Yeung director C/O BEIJING MED-PHARM CORPORATION 600 WEST GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
David Hui Li director C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017
Min Fang director UNIT 2206, BUND CENTER OFFICE TOWER NO. 222 YANAN ROAD (EAST) SHANGHAI F4 200002
Zhijun Tong director C/O BMP SUNSTONE CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Joseph Chow director 10110 SORRENTO VALLEY ROAD SUITE C SAN DIEGO CA 92121
Yungang Lu director 4TH FLOOR, ZHONGDIAN INFORMATION TOWER 6 ZHONGGUANCUN S. ST., HAIDIAN DIST. BEIJING F4 100086
Warburg Pincus Llc 10 percent owner 450 LEXINGTON AVENUE, NEW YORK NY 10017
Wp X Biologics Llc director, 10 percent owner C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK X1 10017
Warburg Pincus X Partners, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus Private Equity X, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X Gp L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017

China Biologic Products Holdings (China Biologic Products Holdings) Headlines